Variables in models can provide invaluable insights to disease

Article

There is value in studying a model of human disease that is not a carbon copy, said Jayakrishna Ambati, MD, associate professor, School of Medicine, and vice chairman, Department of Ophthalmology and Visual Sciences, University of Kentucky, Lexington.

There is value in studying a model of human disease that is not a carbon copy, said Jayakrishna Ambati, MD, associate professor, School of Medicine, and vice chairman, Department of Ophthalmology and Visual Sciences, University of Kentucky, Lexington.

Dr. Ambati defended animal models of age-related macular degeneration despite differences in eye structure and disease development between humans and other species often used in testing, such as primates, mice, and rabbits.

"Even imperfect models can provide invaluable insights," he said.

The validity of an animal model can be measured by several variables: face validity, or how well it copies the human condition; whether it obeys the genetic aspects of the disease; and how well it parallels the immunologic and pathogenetic mechanisms.

"This betrays the clinician's bias, but what is most important is how well it tells us something we didn't already know," Dr. Ambati said. "What does it predict, either about mechanisms or about treatment or diagnosis? Does it ultimately reveal some novel insights?"

He added that there is no single best choice of a model but that ongoing dialogue between basic scientists and clinical investigators will continue to lead to new discoveries.

He added that although mice lack maculas, several important insights have been gained from mouse models recently on issues such as development of choroidal neovascularization via substances found in drusen.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Related Content
© 2025 MJH Life Sciences

All rights reserved.